XOMA Royalty (XOMA) said Tuesday it has acquired a 50% economic interest in all future milestones and royalties associated with more than 60 early-stage programs under Twist Bioscience's (TWST) biopharma business for an upfront payment of $15 million.
The deal brings XOMA's portfolio to over 100 assets ranging from commercial therapeutics to pre-clinical programs, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。